Bloomberg Law, December 22, 2021: The FDA authorized Pfizer Inc.’s pill to treat Covid-19 without first getting input from an expert advisory panel. We explain why that could further undermine trust in an agency already facing scrutiny over its rapid decision-making during the pandemic.
Read More »Tag: covid
Equal Access to Merck Covid Pill Imperiled by Prescribing Rules
Bloomberg Law, December 2, 2021: Merck’s antiviral drug molnupiravir—if authorized by the agency—would offer for the first time in the U.S. an at-home treatment option for patients with mild to moderate Covid-19 who are at risk of severe disease.
Read More »NCHR’s Testimony to FDA About Molnupiravir for COVID-19
November 30, 2021: For molnupiravir, the balance of benefits and risks may differ between different types of patients, and not all types of patients were studied.
Read More »Improving the Accuracy of COVID-19 Media Coverage
In response to the COVID-19 pandemic, the National Center for Health Research hosted 9 teleconferences featuring COVID-19 researchers as speakers and discussants on different aspects of COVID-19 of importance to journalists. The main goal of this project was to help journalists understand the nuances of often conflicting information about COVID-19 research, to help ensure accurate media coverage.
Read More »How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
KHN, September 16, 2021: How did Fauci and the NIH and the White House get ahead of the FDA and CDC in backing boosters? NCHR’s president explains the conflicting perspectives. And when the data are not conclusive, the question is what is the best strategy for you? And to defeat the pandemic? They may not be the same.
Read More »